Avalo Therapeutics posts lower-than-expected 2025 net loss

Avalo Therapeutics

23/03/2026 11:12

Overview

U.S. IL-1β drug developer's 2025 net loss is lower than expected

Operating expenses rose due to increased R&D for Phase 2 LOTUS trial

Outlook

Company expects cash and investments at Dec 31, 2025, to fund operations into 2028

Result Drivers

R&D SPENDING - Research and development expenses rose $25.6 mln yr/yr due to costs related to and supporting the Phase 2 LOTUS trial

G&A EXPENSES - General and administrative expenses increased $5.7 mln yr/yr, primarily due to stock-based compensation and headcount additions

WARRANT IMPACT - Net loss widened yr/yr, partly due to a $38.7 mln change in other (expenses) income related to warrants issued in the March 2024 private placement

Company press release: ID:nGNX5NP04m

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Net Income
Beat
-$78.26 mln
-$80.98 mln (9 Analysts)
FY Pretax Profit
Beat
-$78.09 mln
-$80.71 mln (8 Analysts)
FY Operating Expenses
$72.98 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Avalo Therapeutics Inc is $36.00, about 168.3% above its March 20 closing price of $13.42

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)